Latest Interventional cardiology Stories
ALBANY, New York, March 4, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com), "Implantable Drug Delivery Devices (Contraceptives, Drug Infusion Pumps, Intraocular Implants, Drug Eluting, Bio-absorbable Stents, Biodegradable) Market- Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018," in 2011, the global market for implantable drug delivery devices was calculated at...
OhioHealth Riverside Methodist Hospital is nation's first to use recently-approved drug-coated stent COLUMBUS, Ohio, Feb. 28, 2013 /PRNewswire/ -- OhioHealth Riverside Methodist Hospital is now treating patients with peripheral artery disease (PAD) with the first drug-eluting stent to be used outside of the heart. Cook Medical's Zilver PTX is a drug-coated stent that is used to reopen a long thigh artery, located above the knee (the femoropopliteal artery), narrowed or blocked due...
FRAMINGHAM, Mass. and SYDNEY, Feb. 28, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Raymond James 34(th) Annual Institutional Investors Conference at 1:05 p.m. Eastern Standard Time on Tuesday, March 5, 2013. The conference is being...
Together, SynCardia's 70cc and 50cc Total Artificial Hearts Will Fit Almost All Adult Men and Women, and Many Adolescents TUCSON, Ariz., Feb. 28, 2013 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that the U.S. Food and Drug Administration (FDA) has approved two Humanitarian Use Device (HUD) designations for the new 50cc Total Artificial Heart...
-- Phase II, randomized, placebo-controlled, multi-center study will measure the primary efficacy endpoint of reduction in ventricular remodeling post-percutaneous coronary intervention (PCI) -- TORONTO, Feb. 27, 2013 /PRNewswire/ -- CellAegis Devices, Inc., announced today that it has received an Investigational Testing Approval (ITA) from Health Canada that allows the initiation of clinical testing in Canada of the Company's autoRIC(TM) Device for Chronic Remote Ischemic...
Clinical trial to determine if chest closure device leads to better bone healing following cardiac surgery KANSAS CITY, Mo., Feb. 25, 2013 /PRNewswire-USNewswire/ -- Patients undergoing open heart procedures such as coronary artery bypass or valve surgery may be eligible to enroll in a clinical trial available in the Kansas City area only at Saint Luke's Mid America Heart Institute. The SternaLock® Blu clinical trial will compare patients whose sternum (breastbone) is closed with...
According to a new market report published by Transparency Market Research "Interventional Cardiology Devices Market (Bare Metal/Drug Eluting/Bio-absorbable Stents, PTCA Balloons, Scoring Balloons, Guidewires, Guiding Catheters, Angiography Catheters, IVUS, Balloon Inflation Devices) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018," the global market for interventional cardiology devices was calculated at USD 15.8 billion in 2011 and is expected to grow...
Jason Pierce, MSN, MBA, RN for redOrbit.com – Your Universe Online A study recently published in the journal Radiology reports that coronary computerized tomography angiography (CCTA) may be used as a reliable, noninvasive alternative to traditional coronary angiography for assessing risk of heart attack in patients with no medically modifiable risk factors. “CCTA should be considered as an appropriate first-line test for patients with atypical chest pain and suspected but not...
FORT LAUDERDALE, Fla., Feb. 20, 2013 /PRNewswire/ -- OrbusNeich today announced that OrbusNeich Medical GmbH and Orbus International B.V., subsidiaries of OrbusNeich Medical, Inc., (collectively, "OrbusNeich") have commenced patent infringement actions in Germany and The Netherlands against Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific") and its distribution affiliates in those countries. The Complaints allege that Boston Scientific infringed two European patents...
ALBANY, New York, February 19, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Interventional Cardiology Devices Market (Bare Metal/Drug Eluting/Bio-absorbable Stents, PTCA Balloons, Scoring Balloons, Guidewires, Guiding Catheters, Angiography Catheters, IVUS, Balloon Inflation Devices) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018," the global market for...
